Background
==========

Women with systemic lupus erythematosus (SLE) have increased rates of subclinical atherosclerosis and cardiovascular (CV) events \[[@B1],[@B2]\]. Circulating adhesion molecules (CAMs) have been associated with subclinical atherosclerosis in SLE patients \[[@B3],[@B4]\]. We investigated the significance of CAMs in subclinical atherosclerosis progression, as measured by the coronary artery calcium score (CAC) and aorta calcium score (AS) in women with SLE.

Methods
=======

Baseline data collected include demographics and circulating adhesion molecule levels. SLE factors collected included modified SLICC/ACR-DI Damage Index (SDI) (excluding CV outcomes). CAC and AS were measured by electron beam or multidimensional computed tomography at baseline and at one follow-up visit in the Study of Lupus Vascular and Bone Long-Term Endpoints (SOLVABLE). High-risk CAC and AS were defined as CAC \>10 and AS \>100, respectively. Progression in CAC and AS at follow-up was defined as CAC \>10 or AS \>100 and \>10% increase from baseline. Univariate regression models of CAC and AS with risk factors were examined, and further adjusted for age. CAMs measured were ICAM-1, VCAM-1, soluble E-selectin (sESEL), and CD40L.

Results
=======

Imaging at baseline and follow-up were performed on 142 subjects; baseline AS scans were not performed in 36 subjects (Table [1](#T1){ref-type="table"}). Adhesion molecule levels (Table [2](#T2){ref-type="table"}) and imaging marker progression (Table [3](#T3){ref-type="table"}) results are presented. In age-adjusted models, only sESEL was significantly associated with AS and CAC progression (Table [4](#T4){ref-type="table"}).

###### 

Baseline demographics

                   Age (years)   Disease duration (years)   SLEDAI      SDI         Follow-up time (years)
  ---------------- ------------- -------------------------- ----------- ----------- ------------------------
  CAC (*n*= 142)   43.3 ± 9.9    12.0 ± 8.4                 3.8 ± 3.5   1.5 ± 1.6   3.25 ± 0.35
  AS (*n*= 106)    42.2 ± 9.3    12.0 ± 8.5                 4.2 ± 3.6   1.6 ± 1.7   3.26 ± 0.35

Data presented as mean ± SD.

###### 

Baseline circulating adhesion molecules

                CAC (*n*= 142)        AS (*n*= 106)
  ------------- --------------------- --------------------
  ICAM-1        279.9 ± 91.34         276.83 ± 85.79
  VCAM-1        978.0 ± 352.15        973.69 ± 360.05
  sESEL         62.45 ± 28.70         63.81 ± 26.89
  CD40 ligand   5,984.11 ± 2,971.26   6,026.31 ± 2,885.9

Data presented as mean ± SD.

###### 

Imaging marker progression

                   Low risk at baseline   High risk at baseline                                   
  ---------------- ---------------------- ----------------------- --------- ----------- --------- -----------
  CAC (*n*= 142)   103 (72.5)             12 (8.5)                2 (1.4)   21 (14.8)   4 (2.8)   33 (23.2)
  AS (*n*= 106)    67 (63.2)              12 (11.3)               4 (3.8)   23 (21.7)   0         35 (33.0)

###### 

Adhesion molecules regressed against progression in coronary artery calcium score and aorta calcium score

                CAC progression       AS progression
  ------------- --------------------- ---------------------
  ICAM-1        0.97 (0.63 to 1.45)   1.30 (0.81 to 2.13)
  VCAM-1        1.30 (0.69 to 2.41)   1.85 (0.94 to 3.75)
  sESEL         1.68 (1.03 to 2.80)   1.94 (1.08 to 3.60)
  CD40 ligand   1.01 (0.65 to 1.56)   0.91 (0.56 to 1.44)

**^a^**Basis for calculation of OR is 1 SD difference.

Conclusion
==========

A higher level of sESEL is associated with progression in AS and CAC in women with SLE. While previous studies have shown CAMs association with subclinical atherosclerosis \[[@B3],[@B4]\], these results suggest sESEL may predict progression of subclinical atherosclerosis, as measured by AS and CAC, in women with SLE.
